HER2in solid tumors: more than 10 years under the microscope; where are we now?
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HER2in solid tumors: more than 10 years under the microscope; where are we now?
Authors
Keywords
-
Journal
Future Oncology
Volume 10, Issue 8, Pages 1469-1486
Publisher
Future Medicine Ltd
Online
2014-07-23
DOI
10.2217/fon.14.19
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer
- (2017) Yuanming Lu et al. Cancer Biomarkers
- Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer
- (2013) C. Chung et al. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
- Prognostic Role of Human Epidermal Growth Factor Receptor in Gastric Cancer: A Systematic Review and Meta-analysis
- (2013) Cheng Chen et al. ARCHIVES OF MEDICAL RESEARCH
- HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients
- (2013) V Martin et al. BRITISH JOURNAL OF CANCER
- Optimal Targeting of HER2–PI3K Signaling in Breast Cancer: Mechanistic Insights and Clinical Implications
- (2013) Brent N. Rexer et al. CANCER RESEARCH
- Pertuzumab: Optimizing HER2 Blockade
- (2013) O. Metzger-Filho et al. CLINICAL CANCER RESEARCH
- First FDA Approval of Dual Anti-HER2 Regimen: Pertuzumab in Combination with Trastuzumab and Docetaxel for HER2-Positive Metastatic Breast Cancer
- (2013) G. M. Blumenthal et al. CLINICAL CANCER RESEARCH
- Trastuzumab Emtansine: First Global Approval
- (2013) Anita Ballantyne et al. DRUGS
- Pertuzumab for the treatment of metastatic breast cancer
- (2013) Simon P Langdon et al. Expert Review of Anticancer Therapy
- American Society of Clinical Oncology highlights 2013: breast cancer and gynecological malignancies
- (2013) Nadia Harbeck Future Oncology
- Trastuzumab emtansine in the treatment of HER-2-positive metastatic breast cancer patients
- (2013) Claudia Bighin et al. Future Oncology
- Her2 Amplification in Gastric Cancer Is a Rare Event Restricted to the Intestinal Phenotype
- (2013) Carolina Cruz-Reyes et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
- (2013) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- Lung Cancer That Harbors an HER2 Mutation: Epidemiologic Characteristics and Therapeutic Perspectives
- (2013) Julien Mazières et al. JOURNAL OF CLINICAL ONCOLOGY
- Chromosome 17 polysomy: correlation with histological parameters andHER2NEUgene amplification
- (2013) Maria Orsaria et al. JOURNAL OF CLINICAL PATHOLOGY
- Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis
- (2013) Hedyeh Shafi et al. JOURNAL OF CLINICAL PATHOLOGY
- Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies
- (2013) A. B. Hanker et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Neoadjuvant Chemotherapy and Targeted Therapy in Breast Cancer: Past, Present, and Future
- (2013) Simon P. Gampenrieder et al. Journal of Oncology
- Colorectal Cancer: Molecular Mutations and Polymorphisms
- (2013) Aga Syed Sameer Frontiers in Oncology
- Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment
- (2013) Grit S. Herter-Sprie et al. Frontiers in Oncology
- HER2Gene Amplification in Breast Cancer
- (2012) Jane Starczynski et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- HER2Amplification in Gastroesophageal Adenocarcinoma
- (2012) Oana M. Radu et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Overcoming resistance and restoring sensitivity to HER2-targeted therapies in breast cancer
- (2012) M. S. N. Mohd Sharial et al. ANNALS OF ONCOLOGY
- Assessing HER2 amplification by IHC, FISH, and real-time polymerase chain reaction analysis (real-time PCR) following LCM in formalin-fixed paraffin embedded tissue from 40 women with ovarian cancer
- (2012) Thore Hillig et al. APMIS
- HER2/neuGene Amplification and Protein Overexpression in Gastric and Gastroesophageal Junction Adenocarcinoma: A Review of Histopathology, Diagnostic Testing, and Clinical Implications
- (2012) Jaclyn F. Hechtman et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Frequent Mutational Activation of the PI3K-AKT Pathway in Trastuzumab-Resistant Breast Cancer
- (2012) S. Chandarlapaty et al. CLINICAL CANCER RESEARCH
- Advanced HER2-positive gastric cancer: Current and future targeted therapies
- (2012) Roberto A. Pazo Cid et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Primary systemic therapy in HER2-amplified breast cancer: a clinical review
- (2012) Mustafa Khasraw et al. Expert Review of Anticancer Therapy
- Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial
- (2012) Paul E Goss et al. LANCET ONCOLOGY
- ‘Genetic heterogeneity’ in HER2/neu testing by fluorescence in situ hybridization: a study of 2522 cases
- (2012) Martin C Chang et al. MODERN PATHOLOGY
- Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas
- (2012) Eun Yoon Cho et al. MODERN PATHOLOGY
- Heterogeneity of ERBB2 amplification in adenocarcinoma, squamous cell carcinoma and large cell undifferentiated carcinoma of the lung
- (2012) Tobias J Grob et al. MODERN PATHOLOGY
- Lapatinib for Advanced or Metastatic Breast Cancer
- (2012) F. L. Opdam et al. ONCOLOGIST
- Frequency of HER2 Heterogeneity by Fluorescence In Situ Hybridization According to CAP Expert Panel Recommendations
- (2011) Kimberly H. Allison et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Gastroesophageal Cancer: Correlation Between Immunohistochemistry and Fluorescence In Situ Hybridization
- (2011) Laura J. Tafe et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
- (2011) Qingguo Li et al. BMC CANCER
- The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
- (2011) Q Sheng et al. BRITISH JOURNAL OF CANCER
- Marked Response to Single Agent Trastuzumab in a Patient with Metastatic HER-2 Gene Amplified Rectal Cancer
- (2011) Steven M. Sorscher CANCER INVESTIGATION
- Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
- (2011) Mark Barok et al. CANCER LETTERS
- HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
- (2011) Devika Gajria et al. Expert Review of Anticancer Therapy
- Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections*
- (2011) Stephen Lee et al. HISTOPATHOLOGY
- Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
- (2011) Min A Kim et al. HISTOPATHOLOGY
- Genetic alterations and protein expression of HER2 and chromosome 17 polysomy in breast cancer
- (2011) Xiaoli Zhu et al. HUMAN PATHOLOGY
- β-catenin and Her2/neu expression in rectal cancer: association with histomorphological response to neoadjuvant therapy and prognosis
- (2011) Uta Drebber et al. INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
- HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods
- (2011) J. M. S. Bartlett et al. JOURNAL OF CLINICAL PATHOLOGY
- HER2 genetic heterogeneity in breast carcinoma
- (2011) C. Ohlschlegel et al. JOURNAL OF CLINICAL PATHOLOGY
- Targeted therapy with trastuzumab for advanced salivary ductal carcinoma: case report and literature review
- (2011) Orit Kaidar-Person et al. MEDICAL ONCOLOGY
- HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization
- (2011) Christina B Ching et al. MODERN PATHOLOGY
- Impact of chromosome 17 centromere region assessment on HER2 status reported in breast cancer
- (2011) Kristof Egervari et al. PATHOLOGY RESEARCH AND PRACTICE
- Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab
- (2011) K. Yonesaka et al. Science Translational Medicine
- A Molecularly Annotated Platform of Patient-Derived Xenografts ("Xenopatients") Identifies HER2 as an Effective Therapeutic Target in Cetuximab-Resistant Colorectal Cancer
- (2011) A. Bertotti et al. Cancer Discovery
- Assessment of HER2 gene status in breast carcinomas with polysomy of chromosome 17
- (2010) Semir Vranic et al. CANCER
- Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer
- (2010) Rebecca A. Burrell et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- (2010) Ian E. Krop et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- KRAS, BRAF, EGFR and HER2 gene status in a Spanish population of colorectal cancer
- (2010) Marta Herreros-Villanueva et al. MOLECULAR BIOLOGY REPORTS
- HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing
- (2010) Josef Rüschoff et al. VIRCHOWS ARCHIV
- Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients
- (2009) M. Lae et al. ANNALS OF ONCOLOGY
- Associations between ERBB2 amplification and progression-free survival and overall survival in advanced stage, suboptimally-resected epithelial ovarian cancers: A Gynecologic Oncology Group study
- (2009) John Farley et al. GYNECOLOGIC ONCOLOGY
- HER-2 amplification is highly homogenous in gastric cancer
- (2009) Andreas H. Marx et al. HUMAN PATHOLOGY
- Role of Polysomy 17 in Transitional Cell Carcinoma of the Bladder: Immunohistochemical Study of HER2/neu Expression and FISH Analysis of c-erbB-2 Gene and Chromosome 17
- (2009) Sara Simonetti et al. INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY
- Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
- (2009) Guido Sauter et al. JOURNAL OF CLINICAL ONCOLOGY
- Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescencein situhybridization and microarray-based CGH analysis
- (2009) Caterina Marchiò et al. JOURNAL OF PATHOLOGY
- Clinical validation of an array CGH test for HER2 status in breast cancer reveals that polysomy 17 is a rare event
- (2009) I-Tien Yeh et al. MODERN PATHOLOGY
- The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti-HER-2 Therapy and Personalized Medicine
- (2009) J. S. Ross et al. ONCOLOGIST
- HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target
- (2008) C. Gravalos et al. ANNALS OF ONCOLOGY
- Genomic activation of the EGFR and HER2-neu genes in a significant proportion of invasive epithelial ovarian cancers
- (2008) Joanna Vermeij et al. BMC CANCER
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate
- (2008) G. D. Lewis Phillips et al. CANCER RESEARCH
- Assessment of a HER2 scoring system for gastric cancer: results from a validation study
- (2008) M Hofmann et al. HISTOPATHOLOGY
- HER2 testing in the UK: further update to recommendations
- (2008) R A Walker et al. JOURNAL OF CLINICAL PATHOLOGY
- The emerging role of Lapatinib in HER2-positive breast cancer
- (2008) Alice Ulhoa-Cintra et al. Current Oncology Reports
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started